Propositions on the Pharmaceutical Marketing System

Journal of Pharmaceutical Marketing and Management

Volumn 14, Issue 42067, 2002, Pages 75-85

  Paul, Douglas R ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

aggregate marketing system; Marketing propositions; pharmaceutical marketing system

Indexed keywords

EID: 85018930950     PISSN: 08837597     EISSN: 15408574     Source Type: Journal    
DOI: 10.3109/J058v14n03_05     Document Type: Article

References (7)

1. Wilkie WL, Moore ES. Marketing's contributions to society. J Marketing. 1999; 63 (Special Issue): 198 – 218.
2. Hawkins DI, Best RJ, Coney KA. Consumer behavior: Implications for market-ing strategy. 6th ed. New York: Irwin; 1995.
3. National Institute for Health Care Management and Research Foundation. Pre-scription drug expenditures in 2000: The upward trend continues. May 8, 2001.
4. Lichtenberg, FR. The benefits and costs of newer drugs: evidence from the 1996 Medical Expenditure Panel Survey. National Bureau of Economic Research Working Paper No. W8147. March 2001.
5. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: Updating the cost-of-illness model. J Am Pharm Assoc. 2001; 41 (2): 192 – 9.
6. PhRMA. Pharmaceutical companies target the diseases of aging with nearly 700 new medicines in development [resource on World Wide Web]. URL: http://www. phrma.org/publications/documents/factsheets//2000-08-01.179.phtml. Available from Internet. Accessed 2001 Mar 10.
7. Parsons T. The social system. Glencoe, IL: Free Press; 1951.